Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy” | Synapse
May 16, 2026
Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy”
Key Points
The aim is to evaluate how CYP2C19 genotyping affects responses to mavacamten in patients with obstructive hypertrophic cardiomyopathy based on metabolic status.
Analysis of CYP2C19 genotypes in patients with obstructive hypertrophic cardiomyopathy.
Comparison of treatment outcomes for normal, intermediate, and rapid metabolisers.
Review of previous responses and outcomes related to genotyping.
Comments indicate varying outcomes in patients based on CYP2C19 metabolism types.
Highlight the need for tailored treatment approaches based on metabolic profiles.